ANI Pharmaceuticals (NASDAQ:ANIP) Posts Earnings Results, Beats Estimates By $0.17 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) released its quarterly earnings data on Friday. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17, FiscalAI reports. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period last year, the firm earned $1.80 EPS. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI reported record second-quarter revenue of $266 million, up 26% year over year, with adjusted EBITDA up 32% to a record $71.6 million and operating cash flow of $56.7 million.
• The company modestly lowered 2026 Cortrophin Gel revenue guidance to $520 million-$540 million, citing first-half performance, although it maintained expectations for strong second-half growth and reaffirmed total revenue guidance of $1.08 billion-$1.14 billion.
• Cortrophin revenue rose 43% year over year to $117.1 million, while the gout-focused sales-force expansion is showing encouraging early indicators: more than 95% of new representatives generated multiple cases and over one-third of prescribers initiated at least two cases.
• Generics revenue increased 10% to $99.1 million, with 12 products launched year to date and at least 15 expected for 2026; management also highlighted that approximately 95% of revenue comes from products manufactured in the U.S.
• ILUVIEN revenue declined 16% year over year to $18.7 million, primarily due to international shipment timing, though management reaffirmed its full-year guidance and expects more detailed uveitis trial data in the fourth quarter.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP traded down $4.38 during trading on Friday, reaching $78.25. The stock had a trading volume of 1,020,050 shares, compared to its average volume of 293,035. ANI Pharmaceuticals has a 52 week low of $70.15 and a 52 week high of $99.50. The business’s 50-day moving average price is $81.02 and its 200 day moving average price is $79.37. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The stock has a market capitalization of $1.78 billion, a PE ratio of 19.81 and a beta of 0.44.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer owned 174,693 shares of the company’s stock, valued at approximately $14,213,022.48. The trade was a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the sale, the director owned 38,432 shares in the company, valued at $3,098,772.16. The trade was a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 88,029 shares of company stock worth $6,954,472 over the last 90 days. Company insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. boosted its position in ANI Pharmaceuticals by 26.0% in the 4th quarter. Invesco Ltd. now owns 189,836 shares of the specialty pharmaceutical company’s stock valued at $14,986,000 after buying an additional 39,178 shares during the last quarter. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the fourth quarter valued at about $1,243,000. Susquehanna Portfolio Strategies LLC acquired a new stake in ANI Pharmaceuticals in the fourth quarter worth about $906,000. Tang Capital Management LLC increased its position in ANI Pharmaceuticals by 51.6% in the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after purchasing an additional 163,937 shares during the period. Finally, Twinbeech Capital LP bought a new stake in ANI Pharmaceuticals during the 4th quarter worth about $276,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ANIP. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Guggenheim restated a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Canaccord Genuity Group started coverage on ANI Pharmaceuticals in a research note on Thursday, July 16th. They issued a “hold” rating and a $91.00 price target on the stock. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.